2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography

The study evaluated the use of 2-Deoxy-2-[18F]fluoro-D-Glucose Positron Emission Tomography/Computed Tomography ([18F]FDG PET/CT) in 10 canine patients with various malignant tumors to improve staging and patient management. The results showed that in 7 out of 10 dogs, PET/CT findings significantly altered treatment plans and prognoses, such as recommending polychemotherapy for lymphoma due to increased FDG uptake in lymph nodes and canceling surgeries for mammary carcinoma and lung tumors due to detected metastases. Despite challenges like high costs and limited demand in veterinary medicine, the study concluded that FDG PET/CT provided valuable additional information for managing canine cancer and suggested its potential for broader application in comparative oncology. However, the study was limited by a small sample size and the refusal of some owners to pursue further diagnostic steps.